What is a stock summary page? Click here for an overview.
Business Description
Finch Therapeutics Group Inc
NAICS : 325412
SIC : 2834
ISIN : US31773D2009
Description
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical date from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.55 | |||||
| Equity-to-Asset | 0.31 | |||||
| Debt-to-Equity | 2.04 | |||||
| Debt-to-EBITDA | -1.49 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -76.3 | |||||
| 3-Year EBITDA Growth Rate | 7.1 | |||||
| 3-Year EPS without NRI Growth Rate | 13 | |||||
| 3-Year FCF Growth Rate | 4 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 14.05 | |||||
| 9-Day RSI | 24.36 | |||||
| 14-Day RSI | 32.76 | |||||
| 3-1 Month Momentum % | 34.7 | |||||
| 6-1 Month Momentum % | 28.26 | |||||
| 12-1 Month Momentum % | 570.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.87 | |||||
| Quick Ratio | 3.87 | |||||
| Cash Ratio | 3.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.6 | |||||
| Shareholder Yield % | 60.45 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -16873.83 | |||||
| ROE % | -64.48 | |||||
| ROA % | -25.54 | |||||
| ROIC % | -62.4 | |||||
| 3-Year ROIIC % | -19.99 | |||||
| ROC (Joel Greenblatt) % | -72.94 | |||||
| ROCE % | -39.24 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 194.02 | |||||
| PB Ratio | 1.47 | |||||
| Price-to-Tangible-Book | 1.47 | |||||
| EV-to-EBIT | -1.73 | |||||
| EV-to-Forward-EBIT | -0.13 | |||||
| EV-to-EBITDA | -1.75 | |||||
| EV-to-Forward-EBITDA | -0.16 | |||||
| EV-to-Revenue | 318.56 | |||||
| EV-to-Forward-Revenue | 73.6 | |||||
| EV-to-FCF | -1.92 | |||||
| Price-to-GF-Value | 10.32 | |||||
| Earnings Yield (Greenblatt) % | -57.8 | |||||
| FCF Yield % | -86.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:FNCH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Finch Therapeutics Group Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.107 | ||
| EPS (TTM) ($) | -8.82 | ||
| Beta | 1.74 | ||
| 3-Year Sharpe Ratio | 0.28 | ||
| 3-Year Sortino Ratio | 1.6 | ||
| Volatility % | 672.06 | ||
| 14-Day RSI | 32.76 | ||
| 14-Day ATR ($) | 0.340051 | ||
| 20-Day SMA ($) | 13.85334 | ||
| 12-1 Month Momentum % | 570.45 | ||
| 52-Week Range ($) | 0.8 - 15.85 | ||
| Shares Outstanding (Mil) | 1.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Finch Therapeutics Group Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Finch Therapeutics Group Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Finch Therapeutics Group Inc Frequently Asked Questions
What is Finch Therapeutics Group Inc(FNCH)'s stock price today?
The current price of FNCH is $13.00. The 52 week high of FNCH is $15.85 and 52 week low is $0.80.
When is next earnings date of Finch Therapeutics Group Inc(FNCH)?
The next earnings date of Finch Therapeutics Group Inc(FNCH) is 2025-05-09 Est..
Does Finch Therapeutics Group Inc(FNCH) pay dividends? If so, how much?
Finch Therapeutics Group Inc(FNCH) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers